Enliven Therapeutics reports clinical-stage biopharmaceutical developments for a small-molecule oncology pipeline led by ELVN-001, a kinase inhibitor designed to target the BCR::ABL gene fusion in chronic myeloid leukemia. News commonly covers ENABLE clinical-trial updates, CML data presentations, regulatory-development topics, quarterly financial results, and preparation for later-stage development.
Company updates also include leadership and board changes, Nasdaq inducement grants, investor-conference participation, and descriptions of Enliven's precision oncology discovery process built around clinically validated biological targets and differentiated chemistry.
Enliven Therapeutics (Nasdaq: ELVN) will present preliminary Phase 1a/1b ENABLE data on ELVN-001 in chronic myeloid leukemia patients with atypical BCR::ABL1 fusion transcripts at ASH 2025 (Dec 6-9).
As of Apr 28, 2025 six previously treated chronic phase CML patients with atypical transcripts received ELVN-001 (20–80 mg BID; some escalated to 120 mg QD). Four patients were efficacy-evaluable and showed transcript reductions including multiple >1 log decreases, a fall from 0.95% to 0.15%, and durable on-study durations (80–505 days). No treatment-emergent adverse events >Grade 2 were reported in these patients. Presentation details: poster session Dec 7, 6:00–8:00 p.m. ET.
Enliven Therapeutics (Nasdaq: ELVN) announced upcoming presentations of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia.
The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress.
Enliven Therapeutics (Nasdaq: ELVN) reported significant progress in Q2 2025, highlighted by positive Phase 1 clinical trial results for ELVN-001 in chronic myeloid leukemia (CML) treatment. The trial demonstrated a 47% cumulative MMR rate, with 32% of patients achieving MMR by 24 weeks, surpassing historical data from competitor treatments.
The company strengthened its financial position through a $230 million public offering, ending Q2 with $490.5 million in cash and equivalents, extending runway into H1 2029. Quarterly financials showed R&D expenses of $21.5 million and a net loss of $25.3 million. Enliven plans to initiate a Phase 3 pivotal trial in 2026.
Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:
- TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
- Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
- Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET
All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.
The trial showed a 44% cumulative major molecular response (MMR) rate (16 of 36 patients) by 24 weeks, with 26% achieving and 100% maintaining MMR. The study enrolled 74 heavily pretreated patients, with 66% having received three or more prior tyrosine kinase inhibitors (TKIs).
ELVN-001, a selective BCR::ABL1 kinase inhibitor, demonstrated strong efficacy in resistant cases, with 40% of TKI-resistant patients achieving MMR. The drug showed a favorable safety profile across all doses, with low rates of dose interruptions (10%) and reductions (<5%). The results will be presented at the EHA 2025 Congress in Milan.